3 No-Brainer Growth Stocks to Buy in October
Three Fool.com contributors have identified what they believe are no-brainer growth stocks to buy in October. Here's why they ...
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
Between Viking Therapeutics and Summit Therapeutics, investing $1,500 in Viking makes more sense right now, though it is a ...
Morningstar14h
Obesity Drug Market: The Next Wave of GLP-1 Competition
New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...
thedailyupside4h
Weight-Loss Drugs Might Not Tank Medicare After All
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs.
MarketBeat on MSN16h
Why Eli Lilly Stock Is Soaring-and How It Plans to Stay on Top
In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company ...
Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...